ShEEP Request for Imaging Mass Spectrometry System

摘要 弗吉尼亚州贝德福德医院申请资金购买成像质谱仪 (IMS)RapifleX，由Bruker制造。这是基于两个由ORD赞助的请求 由PI组织的实地会议，以促进协作的多地点研究。过半 在14位在大会上展示作品的VA演讲者中，使用的是位于 Bedford VAMC，目前配备了Q Exactive混合Orbitrap MS，Quantiva 三重四极杆MS和一个CyTOF MS系统。这些MS仪器旨在 分析液体样本，但不分析组织切片和固定样本。新的IMS RapifleX将 将成像与基质辅助激光解吸/电离飞行时间质谱仪相结合 单一仪器，成像MALDI-TOF MS，与现有MS完全不同 私家侦探实验室里的仪器。通过添加IMS RapifleX，我们将扩展核心分析 目标从一维识别到二维空间探测的能力 感兴趣的人。该仪器将在多学科临床研究中发挥重要作用 由退伍军人管理局支持，为我们提供了无与伦比的表型和功能能力 分析正常和患病状态下的细胞、啮齿动物材料和人体组织。信息管理系统(IMS) RapifleX将用于由夏博士、斯坦博士和麦基博士指导的多项退伍军人管理局资助的研究 (主要用户)，以及贝德福德退伍军人医院的其他主要调查人员(次要用户) (史密斯博士)和波士顿退伍军人健康系统(科沃尔博士)。IMS RapifleX MS将用于 为中枢神经系统相关研究分析大量生物样本 精神错乱。具体地说，它将被用来确定病理蛋白质的空间分布。 诱导多能干细胞衍生的3D人类神经元和小鼠大脑，然后验证 在死后脑组织中(夏博士；目标1)。IMS RapifleX将用于映像 慢性创伤性脑病受试者脑中的病理蛋白(斯坦博士 和麦基博士；目标2)。IMS RapifleX获得的图像将用于表征 神经元和小鼠脑中的生物标志物及其与脑内病理改变的关系 (目标3)。总之，收购新的IMS RapifleX将使PI能够建立MS 核心和实现培养协作的多地点研究的目标。

Abstract The Bedford VA hospital requests for funds to acquire the Imaging Mass Spectrometer (IMS) rapifleX, manufactured by Bruker. This is based on the request from two ORD-sponsored field based meetings organized by the PI to foster collaborative multi-site studies. More than half of the 14 VA speakers who presented their works at the conference are using MS located at the Bedford VAMC, which is currently equipped with a Q Exactive hybrid Orbitrap MS, a Quantiva Triple Quadrupole MS, and a CyTOF MS system. These MS instruments are designed to analyze fluid samples but not tissue sections and fixed samples. The new IMS rapifleX will combine Imaging with Matrix Assisted Laser Desorption/Ionization Time-Of-Flight MS into a single instrument, Imaging MALDI-TOF MS. It is completely different from existing MS instruments in the PI’s lab. With the addition of IMS rapifleX, we will expand core analytic capability from one-dimensional identification to two-dimensional spatial detection of the targets of interest. This instrument will play an important role in multi-disciplinary clinical studies that are supported by VA, providing us with an unparalleled ability to phenotypically and functionally profile cells, rodent material and human tissue from both normal and diseased states. The IMS rapifleX will be used for multiple VA funded studies directed by Drs. Xia, Stein and McKee (major users), along with other principal investigators (minor users) at the Bedford VA Hospital (Dr. Smith) and Boston VA Health System (Dr. Kowall). The IMS rapifleX MS will be used to analyze a large variety of biological samples for studies related to central nervous system disorders. Specifically, it will be used to determine spatial distribution of pathological proteins in induced pluripotent stem cell-derived 3D human neurons and mouse brains, and then validate them in postmortem brain tissue (Dr. Xia; Aim 1). The IMS rapifleX will be used to image pathological proteins in brains from subjects with chronic traumatic encephalopathy (Dr. Stein and Dr. McKee; Aim 2). Images obtained by IMS rapifleX will be used to characterize biomarkers in neurons and mouse brains and relate them to pathological alteration in brains (Aim 3). In conclusion, acquisition of the new IMS rapifleX will allow the PI to establish an MS core and fulfill the goal of fostering collaborative multi-site studies.